Infection with SARS-CoV-2 or severe acute respiratory syndrome coronarvirus type 2 was highlighted in December 2019 in the city of Wuhan in China, responsible for an pandemic evolution since March 11, 2020. The infection affects all ages of life, although affecting children in a very small proportion of cases. The typical presentation of the disease combines fever (98%), cough (76%), myalgia and asthenia (18%) as well as leukopenia (25%) and lymphopenia (63%). Upper airway involvement is rare.
The main clinical presentation requiring hospitalization of infected patients is that of atypical pneumonia which may require critical care management (27%) and progress to an acute respiratory distress syndrome (67%) involving life-threatening conditions in almost 25% of patients diagnosed with SARS-CoV-2 infection. Other organ damage have been reported, mainly concerning kidney damage (29%) which may require renal replacement therapy in approximately 17% of patients.
Neurological damage has been very rarely studied, yet reported in 36% of cases in a study including patients of varying severity in a China cohort, but they did not use validated tools to identify cognitive failure in this population. All over the world ICU- professionals have experienced that the majority of the ICU patients have presented a severe and agitated delirium, leading to prolonation of the ICU stay and for some of them reintubation has been necessary Study Objectives.
To report the prevalence of delirium at initial management in critical care, to report its
morbidity and mortality and to identify prognostic factors.
What is the prevalence of delirium in ICU Covid-19 patients?
The prevalence of delirium in ICU Covid-19 patients is higher than general ICU
Retrospective international multicenter observational cohort.
Number of subjects:
We expect to include approximately 1000 Covid-19 patients admitted to the participating